Notably, we discovered that an abundance of tumor‐reactive CXCL13+CD8+ Tex cells highly expressed cytotoxic‐related genes (GZMK) and exhausted‐related genes (PDCD1/CTLA4/LAG3/TIGIT), indicating the clinical potential of ICB, especially anti‐PDCD1/CTLA4/LAG3/TIGIT antibodies, in reactivating CXCL13+CD8+ Tex cells to combat tumor cells. This evidence concerns the gene LAG3 and neoplasm.